|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- October 30, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Cardiome Pharma Corp., of Vancouver, British Columbia, and co-development partner Astellas Pharma US Inc., of Deerfield, Ill., started patient enrollment in the ACT 5 trial, a confirmatory Phase III study of Kynapid (vernakalant hydrochloride) injection, in development for the rapid conversion of atrial fibrillation to sinus rhythm. About 450 patients will be recruited, excluding those with evidence or history of congestive heart failure. The study, which the FDA requested following its August 2008 approvable letter, is expected to be completed the first half of 2011. (See BioWorld Today, Aug. 12, 2008.)
o Celldex Therapeutics Inc., of Needham, Mass., reported ...